# A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration

> **NCT06074783** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cellcolabs Clinical LTD.** · enrollment: 30 (estimated)

## Conditions studied

- Musculoskeletal Injury

## Interventions

- **BIOLOGICAL:** Human Allogeneic Bone-Marrow (BM) -Derived Mesenchymal Stromal Cells (MSCs) Product (StromaForte)

## Key facts

- **NCT ID:** NCT06074783
- **Lead sponsor:** Cellcolabs Clinical LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-20
- **Primary completion:** 2027-10-19
- **Final completion:** 2028-10-19
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06074783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06074783, "A Study of Human Allogeneic Bone-marrow Derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Musculoskeletal Injuries and/or Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06074783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*